Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$156.2 million.

  • Avidity Biosciences' Cash from Operations fell 13801.42% to -$156.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$580.5 million, marking a year-over-year decrease of 21465.87%. This contributed to the annual value of -$300.9 million for FY2024, which is 15269.6% down from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Cash from Operations is -$156.2 million, which was down 13801.42% from -$199.7 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Cash from Operations peaked at $16.5 million during Q4 2023, and registered a low of -$199.7 million during Q2 2025.
  • For the 5-year period, Avidity Biosciences' Cash from Operations averaged around -$59.6 million, with its median value being -$39.2 million (2022).
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 14210.62% in 2023, then tumbled by 70524.21% in 2024.
  • Avidity Biosciences' Cash from Operations (Quarter) stood at -$26.2 million in 2021, then plummeted by 49.49% to -$39.2 million in 2022, then soared by 142.11% to $16.5 million in 2023, then crashed by 705.24% to -$99.9 million in 2024, then crashed by 56.37% to -$156.2 million in 2025.
  • Its Cash from Operations stands at -$156.2 million for Q3 2025, versus -$199.7 million for Q2 2025 and -$124.8 million for Q1 2025.